Carboplatin and cisplatin: are they equivalent in efficacy in ?optimal residual? advanced ovarian cancer?
- 1 August 1996
- journal article
- editorial
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 122 (8) , 443-444
- https://doi.org/10.1007/bf01187154
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.Journal of Clinical Oncology, 1994
- Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.Journal of Clinical Oncology, 1993
- Advanced ovarian cancer. Carboplatin versus cisplatin.1993
- Carboplatin versus cisplatinAnnals of Oncology, 1993
- Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.Journal of Clinical Oncology, 1992
- Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1992
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.Journal of Clinical Oncology, 1991
- Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and CarboplatinJNCI Journal of the National Cancer Institute, 1989